I think in the medical, R&D space, it is better. Especially the data repository from Tilray's early entrance and of course, the amount of product that can be leveraged for clinical trials. Unfortunately, we're probably a year out from realizing this advantage. Did you jump back in or are you still waiting? Absent any material news, this will to lower.
Market Data 
Markets 
